Melanóma: vizsgálatok itt: Portugália
7 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 10.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleStudy to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
- Where
- Funchal, Lisbon
- Életkor
- 18 év and over
- People
- 632 worldwide
- Run by
- mAbxience Research S.L.
See details and how to joinNCT07221734 - 1/2. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Lisbon, Porto
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - 2/3. fázisTaking peopleSafety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
- Where
- Coimbra, Lisbon, Porto
- Életkor
- 18 év and over
- People
- 740 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT06697301 · EU 2024-512659-19-00 - 2. fázisTaking peopleA Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
- Where
- Lisbon, Porto
- Életkor
- 18 év and over
- People
- 160 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06961006 - 1/2. fázisTaking peopleA Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Where
- Porto
- Életkor
- 6 hónap to 17 év
- People
- 370 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT02332668 · EU 2022-501257-36-00 - 3. fázisTaking peopleRandomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 (Proposed Nivolumab Biosimilar) Versus EU-/US-Opdivo in Subjects With Previously Untreated Advanced (Unresectable or Metastatic) Melanoma (LEON Study)
- Where
- Funchal, Lisbon
- Életkor
- 18 év and over
- People
- 119 worldwide
- Run by
- Mabxience Research S.L.
See details and how to join2025-521562-95-00 · EU 2025-521562-95-00 - 3. fázisTaking peopleIMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
- Where
- Coimbra, Lisbon
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Immunocore Ltd
See details and how to joinNCT06112314